EagleBio Biomarker Spotlight:  ADMA




What is ADMA?

ADMA the abbreviation for asymmetric dimethylarginine and it is endogenous molecule which can be detected in human blood and urine. It shows structural homology to the amino acid L-arginine, and it acts as an inhibitor of nitric oxide (NO) synthesis. (5,6)

In fact, various studies performed in vitro and in vivo have confirmed and demonstrated that ADMA concentration-dependently inhibits NO production.(3,5)  Böger RH et al. 2004 study discusses the mechanism of the modulation of NOS activity. This study describes how the inhibition of the enzyme that inactivates ADMA, dimethylarginine dimethylaminohydrolase (DDAH), thereby elevating ADMA levels and causing vasoconstriction of isolated arterial rings in vitro. (2)  DDAH’s role in degradation of ADMA is the major pathway for its elimination however, a small amount is eliminated by renal excretion. (4)

Pathophysiological Role of ADMA
The vascular endothelium plays a central role in the regulation of vascular structure and function, mainly due to the formation of endothelium-derived nitric oxide (NO). NO has been named an “endogenous anti-atherogenic molecule” due to its diverse regulatory functions in vascular homeostasis. In fact, ADMA has been found to cause vasoconstriction when it is infused intraarterially. NO is formed by the enzyme NO synthetase (NOS) from the amino acid precursor L-arginine and it plays a large role within cardiovascular system. NOS activity can be down-regulated by asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS as described above. (3,5,6)


In past studies, patients with end-stage chronic renal failure and have little or no urine output, elimination is thus blocked and as a result circulating concentrations of ADMA rise appropriately to inhibit NO synthesis. The accumulation of ADMA is thought to lead to impaired NOS synthesis as described above this is theorized to be a contributing factor to hypertension and immune dysfunction associated with chronic renal failure. (4)  In addition to ADMA’s effects on vasodilation, a rise in circulating ADMA levels lead to an increased resting vascular tone. It also enhances several pro-atherogenic mechanisms including platelet aggregation and adherence of monocytes, proliferation of vascular smooth muscle cell, as well as extracellular matrix formation. (4)


The effects of ADMA on NO synthesis and NO-mediated pathophysiological processes have been described in numerous experimental studies. Moreover, elevated ADMA levels in plasma have been found in clinical studies including patients with hypercholesterolemia, hypertension, chronic heart failure, chronic renal failure and other internal disorders. Recent prospective and cross-sectional studies indicated that elevated ADMA levels are a risk factor for future cardiovascular eve
nts and total mortality. ADMA may have diagnostic relevance as a novel cardiovascular risk marker. (2,3)



Diseases Associated with Elevated ADMA Levels:

  • Coronary Artery Disease
  • Chronic Renal Failure and Hemodialysis Treatment
  • Peripheral Arterial Occlusive Disease
  • Chronic Heart Failure
  • Hypertensive patients
  • Diabetes Mellitus
  • Lipid Disorders
  • Preeclampsia
  • Erectile Dysfunction


What Methods can be used to Measure ADMA?

Eagle Biosciences offers many options for researchers looking to measure ADMA:


References:

  1. Antoniades,
    C et al. “ Asymmetrical dimethylarginine regulates endothelial function in
    methionine-induced but not in chronic homocystinemia in humans: effect of
    oxidative stress and proinflammatory cytokines.”
    Am. J. Clin. Nutr. 2006; 84: 781-788. https://ajcn.nutrition.org/content/84/4/781.full
  2. Böger
    RH et al. “Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide
    Synthase, Explains the “l-Arginine Paradox” and Acts as a Novel Cardiovascular
    Risk Factor.”
    J. Nutr. 2004; 134 no. 10 2842S-2847S.https://jn.nutrition.org/content/134/10/2842S.long
  3. Böger
    RH et al. “Asymmetric dimethylarginine: a novel risk factor for endothelial
    dysfunction. Its role in hypercholesterolemia.”
    Circulation 1998; 98: 1842 – 1847.https://cardiovascres.oxfordjournals.org/content/59/4/824.full.pdf+html
  4. Krempl
    TK et al. “Elevation of asymmetric dimethylarginine (ADMA) in patients with
    unstable angina and recurrent cardiovascular events.” Eur. Heart J. 2005; 26:
    1846-1851.
    https://eurheartj.oxfordjournals.org/content/26/18/1846.full
  5. Vallance
    P. et al. “ Accumulation of an endogenous inhibitor of NO synthesis in chronic
    renal failure”.
    Lancet 1992; 339: 572
    – 575.
    https://www.ncbi.nlm.nih.gov/pubmed/1347093?dopt=Abstract
  6. Vallance
    P. et al. “ Endogenous dimethyl-arginine as an inhibitor of nitric oxide
    synthesis”.
    J. Cardiovasc. Pharmacol.
    1992; 20 (Suppl. 12): S60 – S62.
    https://jn.nutrition.org/content/134/10/2842S.long


For a Full Listing of Publications utilizing these ADMA ELISA Assay kits, click on the link below:

ADMA ELISA Assay Kit Publications

Related News

Eagle Biosciences announces the product launch of 3 new assays to measure ADMA, SDMA, and L-Arginine in serum and plasma samples. The 3 ELISA kits include ADMA ELISA, the most widely published ADMA assay on the market, SDMA ELISA with a sensitivity of 0.05 µmol/L, and ADMA & Arginine ELISA which is intended for the quantitative determination of both endogenous ADMA as well as L-Arginine in EDTA-Plasma on 2 different 96-well microplates.

Previously, ADMA was measured by HPLC or LC-MS methods that were focused on the chromatographic separation of the structurally similar but functionally different SDMA and ADMA isomers. These HPLC methods were successful, but were largely expensive and laborious. This ADMA ELISA kit was developed with a very specific and sensitive rabbit anti-ADMA antibody that allows for excellent correlation with these LC-MS methods. ADMA is the abbreviation for asymmetric dimethylarginine while SDMA is the abbreviation for symmetric dimethylarginine.

“Eagle is very excited to now offer the ADMA, SDMA, and the new ADMA / Arginine ELISA kits”, said Dan Keefe, President of Eagle Biosciences. “These are the best ADMA assays in the world because they are easy to perform with virtually no cross reactivity to other forms of arginine while still correlating with LC-MS. This is great news for researchers.”

Eagle is offering promotional pricing for the next few months for researchers measuring ADMA, SDMA, or Arginine. These assay kits are currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for full details.

Eagle Biosciences, Inc. is pleased to announce the product launch of 7 new Vitamin HPLC Assay Kits. These high quality kits provide results in under an hour while cost per sample remains affordable. Included in this launch are: Vitamin A & Vitamin E HPLC Assay, Vitamin B1 (Thiamine Pyrophosphate) HPLC Assay, Vitamin B2 (Riboflavin) HPLC Assay, Vitamin B6 HPLC Assay, Vitamin C HPLC Assay, 25-OH Vitamin D HPLC Assay, and Vitamin K1 HPLC Assay. To complete the product offerings, HPLC columns and controls are also available through Eagle Biosciences.

Dan Keefe, President of Eagle Biosciences, is thrilled about the launch of these kits, “This is an exciting time for Eagle. In the last few months, we have launched the innovative Mouse Monoclonal Antibody Isotyping ELISA along with the unique Cytokeratin Assays from IDL Biotech and now we are proud to introduce these high quality vitamin assays that are as simple to run as they are cost effective.”

Eagle anticipates offering promotional pricing in the coming months for researchers measuring Vitamin A, Vitamin B1, Vitamin B2, Vitamin B6, Vitamin C, 25-OH Vitamin D, Vitamin E, and Vitamin K1. These assay kits are currently for research use only.

Eagle Biosciences, Inc. has announced the product launch of two new catecholamine ELISA kits. The catecholamine kits are Vanillylmandelic Acid (VMA) ELISA and Homovanillic Acid (HVA) ELISA which will be the most sensitive and highly specific on the market. Both the VMA ELISA and HVA ELISA include a full standard set with a dynamic range of 0.0625 -8 µg/ml for VMA and 0.125-16 µg/ml for HVA.

Dan Keefe, President of Eagle Biosciences, is very excited about these new ELISA kits, “This is an exciting time for Eagle. We just launched the innovative Mouse Monoclonal Antibody Isotyping ELISA in April 2011 and now we can introduce the Vanillylmandelic Acid (VMA) and Homovanillic Acid (HVA) ELISA kits. They are developed and manufactured in the USA, are simple to run, and yield quantifiable results in under 2 hours.”

For more information on the VMA ELISA, the HVA ELISA, or any of the products from Eagle Biosciences, visit the website at www.EagleBio.com or call at 866-411-8023.

Eagle Biosciences, Inc. is proud to introduce a new Mouse Monoclonal Antibody Isotyping ELISA kit. The Mouse Monoclonal Antibody (mAb) Isotyping assay kit is designed for the quick and easy identification of both mouse immunoglobulin subclass and light chain. Utilizing a simple 96 well (8×12) ELISA format, up to 12 individual samples can be determined per 96 strip-well plate for heavy chain anti-IgG1, IgG2a, IgG2b, IgG3, IgA, and IgM as well as light chain kappa and lambda. One sample is used per strip utilizing a traditional ELISA plate reader.

“This ELISA kit has excellent specificity for each subtype and results can be produced in about a hour while keeping costs per sample below $6.”said Dan Keefe, President of Eagle,”This product is just the tip of the iceberg for Eagle. We are thrilled about this product launch because it represents the first of a line of Eagle developed assays that will isotype individual mouse monoclonal antibody subclasses.” Eagle expects to introduce individual ELISA based assays for the mouse monoclonal antibody isotypes as soon as this summer.”

The Eagle Mouse Monoclonal Antibody Isotyping ELISA kit is available in convenient 1 plate, 5 plate, or custom bulk sizes and is priced very competitively. For more information on this kit or any of the products from Eagle Biosciences, visit the website at www.EagleBio.com or call at 866-411-8023.

Eagle Biosciences introduces new ultrasensitive Steroid Saliva ELISA kits that will allow for quantification of many samples that were previously undetectable with a traditional steroid saliva assay. The list of new immunoassays includes Ultrasensitive Salivary Cortisol ELISA and Ultrasensitive Salivary DHEA-S ELISA with Ultrasensitive Salivary Testosterone ELISA, Ultrasensitive Salivary Progesterone ELISA, and Ultrasensitive Salivary Estradiol ELISA coming soon.

Dan Keefe, President of Eagle, is excited about the new products, “We are thrilled to offer the new assays as they could change the way researchers measure salivary Cortisol, Testosterone, Progesterone, Estradiol, and DHEA-S. In addition to their sensitivity, the steroid kits are easy to run and will provide results in less than 3 hours.”

For more information on these kits or any of the products from Eagle Biosciences, visit our website at www.EagleBio.com or call us at 617-419-2019.

April 17, 2014:  Eagle Biosciences, Inc. is pleased to announce the product launch of a new Homoarginine ELISA assay kit which will be the first commercially available ELISA kit for homoarginine for researchers. Homoarginine is a non-essential cationic amino acid which is formed from lysine and show characteristics similar to arginine.

Dan Keefe, President of Eagle Biosciences, is thrilled about the launch of this kit, “This is an exciting time for Eagle. Studies have identified homoarginine as a potentially useful predictor of cardiovascular events and mortality as well as a possible indicator of chronic kidney disease. The homoarginine assay is a perfect complement to the gold standard assays we offer for ADMA, SDMA, and Arginine.”

Eagle anticipates offering promotional pricing in the coming months for researchers measuring Homoarginine, ADMA, SDMA, or Arginine. These assay kits are currently for research use only. 

February 2, 2014: Eagle Biosciences is excited to announce the product launch of two new assays: Big Endothelin-1 ELISA Assay Kit and Endothelin 1-21 ELISA Assay Kit. These ELISAs were developed and are manufactured by Biomedica Gruppe in Austria. Biomedica is at the forefront of innovation in research assays, delivering unique and reliable cardiovascular and bone metabolism immunoassays for researchers around the world. The Endothelin 1-21 ELISA and Big Endothlin-1 ELISA are just a couple of the multiple premier assays in Biomedica’s cardiovascular product line that not only offer direct measurement of these analytes but also provide a flexibility to run manually or in an automated system.

The Endothelin 1-21 ELISA Assay kit is designed for the detection and quantification of biologically active Endothelin 1-21. Big Endothelin-1, on the other hand is designed for the detection and quantification of the biologically inactive peptide and 38 amino-acid precursor, Big Endothelin-1. Some researchers believe that Big Endothelin-1’s huge advantage is its prolonged half-life of 30 minutes compared to endothelin, which is approximately 1.5 minutes. Collectively, these assays provide a comprehensive means to accurately and easily measure the endothelin system and circulating concentrations of endothelin. In addition, these products further expand Eagle’s growing Cardiac and Oxidative Stress product lines.

“Endothelin 1-21 and Big Endothelin-1 biomarkers are becoming increasingly more valuable in various areas of research and may ultimately play a significant role in the development and maintenance of anti-endothelin therapy.” said Dan Keefe, President of EagleBio. He continued, “There are several key attributes of these kits such as excellent sensitivity, use with multiple sample types, and small sample volume requirements which make these assay kits excellent tools for the evolving research in this field.”

Eagle is offering promotional pricing for researchers measuring Endothelin 1-21 and Big-Endothelin-1 through the next few months. These products are currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for full details.

December 12, 2013: Eagle Biosciences announces the product launch of a new Anti-Zinc Transporter 8 ELISA.   This assay was carefully designed to utilize the ability of ZnT8 Abs to act divalently and to form a bridge between immobilized ZnT8 and ZnT8.

Anti-Zinc Transporter 8 ELISA Assay kit is capable of detecting and quantifying autoantibodies specific to R 325, W 325, or to residue 325 non-specific variants. This assay specificity was designed based on comprehensive human population gene polymorphism research in the field that supports human sera’s reaction to the alleles encoded with these three protein variants. This product further expands Eagle’s Endocrine product line and more specifically, it complements the other circulating autoantibody kits in this line: IAA ELISA Assay Kit, Anti-GAD (Glutamic Acid Decarboxylase) ELISA Assay Kit, and the Anti IA2 ELISA Assay Kit.

“Anti-Zinc Transporter 8, otherwise known as ZnT8 is a novel maker and a new antigenic target for Type 1 Diabetes,” said Dan Keefe, President of Eagle Biosciences. He continued, “We are proud to deliver new, unique solutions like our Anti-Zinc Transporter 8 ELISA that will assist our customers and benefit emerging areas of research. I have no doubt that this kit will be useful in studies surrounding the early detection of Type 1 and Type 2 Diabetes.”

Eagle is offering promotional pricing for researchers measuring insulin (Anti-Zinc Transporter 8, IAA, Anti-GAD, and Anti-IA2) through the next few months. This protein is currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for fulDecember 12, 2013:
Eagle Biosciences announces the product launch of a new Anti-Zinc Transporter 8 ELISA.   This assay was carefully designed to utilize the ability of ZnT8 Abs to act divalently and to form a bridge between immobilized ZnT8 and ZnT8.

Anti-Zinc Transporter 8 ELISA Assay kit is capable of detecting and quantifying autoantibodies specific to R 325, W 325, or to residue 325 non-specific variants. This assay specificity was designed based on comprehensive human population gene polymorphism research in the field that supports human sera’s reaction to the alleles encoded with these three protein variants. This product further expands Eagle’s Endocrine product line and more specifically, it complements the other circulating autoantibody kits in this line: IAA ELISA Assay Kit, Anti-GAD (Glutamic Acid Decarboxylase) ELISA Assay Kit, and the Anti IA2 ELISA Assay Kit.

“Anti-Zinc Transporter 8, otherwise known as ZnT8 is a novel maker and a new antigenic target for Type 1 Diabetes,” said Dan Keefe, President of Eagle Biosciences. He continued, “We are proud to deliver new, unique solutions like our Anti-Zinc Transporter 8 ELISA that will assist our customers and benefit emerging areas of research. I have no doubt that this kit will be useful in studies surrounding the early detection of Type 1 and Type 2 Diabetes.”

Eagle is offering promotional pricing for researchers measuring insulin (Anti-Zinc Transporter 8, IAA, Anti-GAD, and Anti-IA2) through the next few months. This protein is currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for full details. l details.

October 1, 2013: Nashua, NH: Eagle Biosciences announces the product launch of 7 new AT1R (Anti-Angiotensin II Receptor I Antibody) ELISA Assay kits. These assays are designed for the simple determination of human Anti-Angiotensin II Receptor I Antibodies in various immunoglobulin subclasses (IgG1, IgG2, IgG3, IgG4, and IgM) for screening in serum and plasma samples. These assay kits expand and complement Eagle’s oxidative stress product line which includes a vast array of assays for prominent biomarkers in the field.

“These ELISA kits have excellent analytical sensitivity, as low as 2.5 U/ml.” said Dan Keefe, President of EagleBio, “We are thrilled about this product launch because antibodies to angiotensin II receptor 1 are associated with multifaceted areas of research such as scleroderma, neurological diseases, and severe vascular rejection. The detection and screening of these antibodies will assist researchers as well as to support, manage, and better understand transplantation medicine, one of the most challenging and complex areas of modern medicine.”

Keefe continued, ” I have confidence that these AT1R ELISA assays will become a remarkable method for researchers in the field. Eagle continually seeks to satisfy the unmet needs of researchers and we have high hopes that these unique assay kits that are designed for human, mouse, or rat samples will do just that.”

Eagle is offering promotional pricing for researchers measuring AT1R (Anti-Angiotensin II Receptor I Antibody) through the next few months. These assay kits are currently for research use only. Check out the Eagle website www.EagleBio.com or call 866-411-8023 for full details.